The psychobiology of anxiolytic drugs - Part 2: Pharmacological treatments of anxiety

Pharmacology and Therapeutics

Volumn 88, Issue 3, 2000, Pages 213-227

  Argyropoulos, Spilios V ^a   Sandford, John J ^a   Nutt, David J ^a  

^a SCHOOL OF MEDICAL SCIENCES   (United Kingdom)

Author keywords

Antidepressants; Anxiety disorders; Benzodiazepines; Buspirone; Future anxiolytics

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANXIOLYTIC AGENT; ATENOLOL; BROFAROMINE; BUSPIRONE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CYPROHEPTADINE; DESIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LORAZEPAM; MOCLOBEMIDE; NEFAZODONE; OXAZEPAM; PAROXETINE; PHENELZINE; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; BENZODIAZEPINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; BEHAVIOR THERAPY; DRUG DEPENDENCE; DRUG EFFECT; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; INSOMNIA; NEUROPATHY; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOBIOLOGY; RELAPSE; REVIEW; SOCIAL PHOBIA; WEIGHT GAIN; ANXIETY DISORDER; PATHOPHYSIOLOGY;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; BENZODIAZEPINES; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 0034351295     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00083-8     Document Type: Review

References (124)

1. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder
2. Efficacy and safety of alprazolam, imipramine and placebo in the treatment of panic disorder. A Scandinavian multicentre study
3. Abecarnil, a new beta-carboline, in the treatment of anxiety disorders
4. A double-blind, randomised placebo-controlled multi-centre study of brofaromine in the treatment of post-traumatic stress disorder
5. Selective serotonin reuptake inhibitors (SSRIs) in panic disorder
6. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial: I. Efficacy in short-term treatment
7. Consensus statement on panic disorder from the international consensus group on depression and anxiety
8. Calcium channel blockers for anxiety disorders?
9. Treatment of anxiety with oral hydroxyzine: An overview
10. Serotonin and panic
11. Inositol treatment for panic disorder: A double-blind placebo-controlled crossover trial
12. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder
13. Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone
14. Brain specific benzodiazepine receptors
15. Core symptoms of post-traumatic stress disorder un-improved by alprazolam treatment
16. Cyproheptadine for combat nightmares in post-traumatic stress disorder and dream anxiety disorder
17. New concepts in benzodiazepine therapy: Rebound anxiety and new indications for the more potent benzodiazepines
18. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder
19. Discontinuation of clonazepam in the treatment of social phobia
20. Treatment of obsessive-compulsive disorder
21. Predicting response to amitriptyline in post-traumatic stress disorder
22. Treatment of social phobia with clonazepam and placebo
23. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalised anxiety disorder
24. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan
25. Assessment of the efficacy of buspirone in patients affected by generalised anxiety disorder, shifting to buspirone from prior treatment with lorazepam: A placebo-controlled, double-blind study
26. Recent clinical trials of hydroxyzine in generalised anxiety disorder
27. Valproate in combat-related post-traumatic stress disorder
28. Current and future drug treatment for posttraumatic stress disorder patients
29. Inositol treatment of obsessive-compulsive disorder
30. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalised anxiety disorder. A 6-month randomised controlled trial
31. CBT and pharmacological treatments of social phobia
32. Treatment of recent trauma survivors with benzodiazepines: A prospective study
33. Venlafaxine treatment of panic disorder: A case series
34. Treatment of social phobia with clonidine
35. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder
36. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?
37. The SSRI discontinuation syndrome
38. The effect of beta adrenergic blocking drugs on speaker's performance and memory
39. Beta-blockers in anxiety disorders
40. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder
41. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder
42. Combined SSRI-moclobemide treatment of psychiatric illness
43. Imipramine and chlordiazepoxide in depressive and anxiety disorders
44. Inositol treatment of post-traumatic stress disorder
45. Moclobemide in social phobia: A double-blind, placebo-controlled clinical study
46. Serotonergic (5-HT2) mediation of anxiety - Therapeutic effects of serazepine in generalised anxiety disorder
47. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic
48. Sertraline for social phobia: A double-blind, placebo-controlled crossover study
49. Clonidine in Cambodian patients with post-traumatic stress disorder
50. Low dose lithium carbonate in the treatment of post-traumatic stress disorder
51. Psychiatric reaction patterns to imipramine
52. Sertraline efficacy in depressed combat veterans with post-traumatic stress disorder
53. A comparison of alprazolam and behaviour therapy in treatment of panic disorder
54. Propranolol and clonidine in the treatment of post-traumatic stress disorder of war
55. Pharmacotherapy for post-traumatic stress disorder using phenelzine or imipramine
56. A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder
57. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
58. Future directions in anxiolytic pharmacotherapy
59. A comparison of buspirone and placebo in relieving withdrawal symptoms
60. Other drug treatments and augmentation therapies for panic disorder
61. Controlled trials of inositol in psychiatry
62. Phenelzine versus cognitive behaviour group therapy in social phobia
63. Phenelzine versus atenolol in social phobia
64. Preliminary study of carbamazepine in post-traumatic stress disorder
65. Randomised placebo-controlled trial of moclobemide, cognitive-behavioral therapy and their combination in panic disorder with agoraphobia
66. Drug treatment of panic disorder
67. Antidepressants in panic disorder and agoraphobia
68. Recent developments in the psychopharmacology of anxiety disorders
69. Agoraphobia: Relative and combined effectiveness of therapist-assisted exposure in vivo and imipramine
70. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics
71. Biological treatments of neuroses
72. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks
73. Clinical and medication outcome after short-term alprazolam and behavioral group
74. Open prospective trial of fluoxetine for post-traumatic stress disorder
75. Differential response patterns to MAO inhibitors and tricyclics
76. Moclobemide in social phobia: A controlled-dose response trial
77. Substance P antagonists: A new treatment for depression?
78. Diazepam alters brain 5-HT function in man: Implications for the acute and chronic effects of benzodiazepines
79. Drug-treatment of chronic anxiety
80. Loss of consciousness and post-traumatic stress disorder
81. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder
82. Current status of pharmacotherapy for PTSD: An effect size analysis of controlled studies
83. Placebo response in anxiety disorders
84. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder
85. The pharmacotherapy of social phobia
86. Anxiolytic potential of benzodiazepine receptor partial agonists
87. A controlled trial of desipramine in 18 men with post-traumatic stress disorder
88. Benzodiazepines for the treatment of panic attacks: A new look
89. Buspirone and diazepam in the treatment of anxiety: A controlled study
90. Antidepressants for the treatment of GAD
91. Gepirone and diazepam in generalised anxiety disorders: A placebo-controlled trial
92. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalised anxiety disorder
93. Treatment of panic disorder with tricyclics and MAOIs
94. A meta-analysis of the effects of venlafaxine on anxiety associated with depression
95. Treatment of anxiety states by antidepressant drugs
96. Buspirone in social phobia
97. Placebo-controlled trial of moclobemide in social phobia
98. Long-term therapeutic use of benzodiazepines: II. Effects of gradual taper
99. Maintenance drug treatment for panic disorder: II. Short- and long-term outcome after drug taper
100. Buspirone: An anxiolytic without sedative effect
101. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: A double-blind placebo-controlled study
102. A controlled trial of phenelzine in post-traumatic stress disorder
103. Medication treatments for panic disorder and social phobia
104. Paroxetine treatment of generalised social phobia (social anxiety disorder): A randomised controlled trial
105. Pharmacotherapy for post-traumatic stress disorder
106. Moclobemide for anxiety disorders: A focus on moclobemide for panic disorder
107. Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder
108. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial
109. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia
110. Fluoxetine in post-traumatic stress disorder
111. Psychopharmacological treatments of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
112. Psychopharmacological treatment of social phobia: A double blind, controlled study with fluvoxamine
113. Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study
114. Pharmacotherapy of social phobia - A controlled study with the reversible MAOI (RIMA) moclobemide and phenelzine
115. Behaviour therapy and benzodiazepines: Allies or antagonists?
116. Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia
117. On the need for standardisation in panic disorder treatment research: Survey of the literature, 1980-1992
118. Controlled comparison of trifluoperazine and chlordiazepoxide in the treatment of anxiety
119. Buspirone in the treatment of post-traumatic stress disorder
120. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder
121. Treatment of phobias: I. Comparison of imipramine hydrochloride and placebo